MAPK Usage in Periodontal Disease Progression

Figure 4

Specific MK2 siRNA in vivo delivery silenced target gene expression and reduced LPS-induced bone loss. (a) A schematic showing overall experimental protocol. (b) MK2 mRNA expression in palate gingiva after 3 and 5 times siRNA in vivo delivery. Results are expressed as mean ± SE (𝑛=5 or 6 rats/group, *𝑃<0.05). (c) Representative μCT images of rat maxillae from indicated treatment groups. ROI for quantitative analysis is highlighted. (d) Volumetric analysis of bone loss levels. (e) Bone mineral density (BMD) analysis of bone loss levels. (*𝑃<0.05, ***𝑃<0.001) [153]. Reproduced with permission.

(a)

(b)

(c)

(d)

(e)